emerg cf triplerx data come initi overweight target
proteostasi recent report posit phase data proprietari cftr potenti
corrector homozyg cf patient nacf
await preliminari phase triplerx includ first-in-class cftr amplifi
also look phase data highest qd qd
cohort full triplerx data phase data top symdeko
data hand proteostasi start registr trial
believ proteostasi win either compet triplerx add-on
exist symdeko patient estim proteostasi hold pro forma cash
million see huge valuat disconnect cf market leader vertex billion
vs proteostasi million initi coverag overweight rate
posit phase data nacf proteostasi recent report posit phase data
proprietari cftr potenti corrector homozyg
cf patient nacf specif cohort
perform best mean improv baselin day
day phase symdeko data homozyg patient show
mean absolut chang baselin week
chang larg observ day proteostasi report data fourth
highest mg cohort
come triplerx data vertex lead develop triplerx treat upward
cf patient vertex report data two phase triplerx trial
next-gen corrector late parallel trial vertex
file nda best regimen approv like late
proteostasi report preliminari phase triplerx data includ first-in-class cftr
amplifi follow full triplerx data
way win full phase data hand anticip proteostasi
commenc registr trial see two potenti path proteostasi
gain approv cf drug firstli see opportun proteostasi gain
approv market proprietari triplerx present anticip triplerx approv
global sale billion secondli could see either
function add-on therapi augment efficaci patient alreadi receiv
vertex symdeko new triplerx regimen end expect two readout
phase symdeko add-on studi
cf competit space proteostasi drug may fail clinic gain regulatori
proteostasi develop drug treat cystic fibrosi
proj ev less net debt
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
emerg cf phase triplerx data first-in-class
amplifi quarter initi overweight target
cystic fibrosi cf caus loss function mutat cystic fibrosi
transmembran conduct regul cftr transmembran chlorid ion
channel proteostasi develop three oral once-daili cftr modul
cftr potenti work open dysfunct cftr cell surfac permit
ion flow cftr corrector permit fold cftr reach cell
surfac membran potenti first-in-class amplifi
increas amount unfold cftr protein upon
act receiv fda breakthrough track orphan drug design
north american cystic fibrosi nacf confer proteostasi report posit
phase combin data show activ compar
better vertex overweight blockbust symdeko specif
dose cohort perform best mean
improv baselin day day phase symdeko
data homozyg patient show mean absolut chang
baselin week chang larg observ day
proteostasi report data fourth highest mg
cohort
cf field move toward tripl combin therapi triplerx treat cf
patient vertex lead combin symdeko ivacaftor tezacaftor plu
next-gen corrector proteostasi triplerx regimen differenti first-in-class
cftr amplifi improv effici cftr translat act
substrat corrector potenti act proteostasi report phase data
first cohort quarter full data
expect triplerx data posit given demonstr
improv ad orkambi
see two potenti path proteostasi gain approv cf drug firstli
see opportun proteostasi gain approv market proprietari triplerx
compet vertex strategi could particularli effect europ
vertex less entrench competitor path current model fda
approv global sale reach billion secondli could see
either function add-on therapi augment efficaci patient
alreadi receiv vertex symdeco even triplerx regimen make therapi
end expect two readout phase symdeko add-on studi pti-
anticip opportun add-on regimen
 major cf patient alreadi receiv vertex therapi
last week proteostasi issu million pti share rais gross proce
million bring pro forma cash million see opportun proteostasi
creat valu report addit cf data advanc pipelin
report initi phase triplerx data homozyg cf
report full phase doubl tripl data homozyg cf
report phase symdeko data homozyg cf
report phase symdeko data homozyg cf
initi registr combin add-on trial
page
initi coverag proteostasi overweight rate price
target base project enterpris valu million less project debt
valu proteostasi proprietari tripl combin triplerx cf regimen
million appli standard multipl sale million
discount back valu triplerx cf europ million
appli multipl sale million discount back
view discount rate appropri could adjust
phase triplerx data
proteostasi end cash million subsequ issu million
pti share rais gross proce million estim proteostasi
hold pro forma cash million subtract estim net debt
million divid project market cap million million
share arriv price target pleas see exhibit
proteostasi trade current valuat million pro forma cash
million equat enterpris valu million industri leader vertex trade
billion billion cash exclud vertex cf comp group trade
averag market cap million enterpris valu million see
opportun proteostasi close valuat gap report addit cf data
advanc pipelin phase trial next year pleas see exhibit
sec document factset corpor compani report piper jaffray estim
prqr pro forma cash share count includ recent equiti offer
pti pro forma cash share count includ recent equiti offer
page
cf autosom recess monogen inherit diseas caus loss function
mutat cystic fibrosi transmembran conduct regul cftr protein
cftr transmembran chlorid ion channel cf character accumul
thicken mucu along epitheli surfac mucu lung cf patient
block airway inhibit oxygen diffus respiratori epithelium
alveoli patient suffer progress loss pulmonari function catalyz acut
episod pulmonari exacerb well frequent bacteri infect
airway persist neutrophil lung inflamm contribut pulmonari declin
damag bronchial tissu inflammatori cytokin elastas rao grigg
child sep thicken mucu
accord cystic fibrosi foundat patient registri approxim
american suffer cf global cf affect patient
higher preval amongst caucasian
cftr mutat class type effect approxim differ
cftr mutat caus cf vast major exceedingli rare pleas
see exhibit import rememb overlap
mutat patient homozyg copi heterozyg copi given
mutat accord cf foundat patient registri data
common mutat account cf patient
class cftr mutat
patient
least
class
creat
move
allow
transfer
chlorid
cftr
creat
misfold
keep
move
creat
move
open
creat
move
function
channel
protein
creat
move
adapt cystic fibrosi foundat
view anoth way approxim cf patient make function cftr
reach cell surfac ion channel open patient well
treat vertex cftr potenti kalydeco ivacaftor bind cftr
cell surfac open ion channel potenti chlorid cl- passag anoth
cf patient produc misfold cftr degrad proteasom
page
measur
reach cell surfac mutat treat combin cftr
corrector more-properli fold cftr transport epithelia potenti
open cftr permit cl- ion flow vertex current approv combin therapi
includ orkambi lumacaftor ivacaftor symdeko ivacaftor tezacaftor
remain patient approxim carri nonsens mutat cftr
gene classifi class nonsens mutat produc function
cftr protein current approv therapi class mutat
believ ultim address pretermin stop codon read-through therapi
mrna gene edit
preclin model efficaci primari hbe cell isol cf patient lung
tissu follow transplant lobectomi autopsi cell exhibit electrophysiolog
defect contribut pathogenesi cf hallmark pathogenesi low cl-
excret lead increas epitheli na fluid absorpt result
decreas surfac hydrat sweat test method clinic diagnosi diseas
level chlorid measur sweat measur greater equal
mmol/l indic cf diagnosi
translat power hbe cell valid vitro studi first-ev
uss chamber assay measur transepitheli current produc kalydeco
hbe cell carri mutat uss chamber assay invent
remain valid tool cf translat research today assay show
kalydeco improv chlorid secret normal hbe cell addit
kalydeco reduc excess na absorpt fluid retent restor surfac
hydrat hbe cultur van goor et al pna
importantli chang sweat chlorid level becom correl biomark
clinic improv lung function chang gold standard measur
lung function cf clinic studi pivot phase trial mean absolut
improv week patient treat
kalydeco clinic data support think uss chamber assay
hbe cell strongli correl lung function clinic fact comprehens
post-hoc analysi combin data kalydeco monotherapi studi exhibit
statist signific correl reduct sweat chlorid level
chang filder et al cyst fibro
fact observ correl relationship vitro activ lung
function result flexibl streamlin fda approv cf due larg
number cftr mutat estim one-third cf patient rare
patient fewer mutat need evolv regulatori path approv
treatment popul size support clinic trial appar
vertex receiv label expans kalydeco base vitro chlorid transport
data fischer rat thyroid cell express differ residu function
mutat ad patient label believ fda flexibl reflect
need drug treat cf mutat enough patient power
clinic trial also offer anoth sourc valid reliabl vitro assay
cf could also see translat effici approv pathway
power correl data deriv hbe cell assay also led observ
multipl cftr modul better one vertex cftr corrector lumacaftor
improv homozyg chlorid secret non-cf hbe cell
page
activ restor correl sweat chlorid cftr process akin
mild cf patient van goor et al pna
subsequ evalu kalydeco combin lumacaftor show doubl activ
hbe cell van goor et al cyst fibro orkambi approv
treat homozyg residu function cf patient
vertex first compani present vitro hbe data support augment activ
ad next-gen corrector potenti corrector doublet nacf
vertex debut preclin data show symdeko combin next-gen
corrector hbe cell improv sweat chlorid
wild-typ activ level achiev kalydeco monotherapi patient
demonstr superior triplerx homozyg minim function
heterozyg het/min mutat previous benefit doublet
therapi sinc data vertex report phase ii result triplerx
regimen homozyg patient show averag improv
baselin day respect keat et al nejm
vertex conduct phase trial triplerx includ
treat cf patient
importantli addit proteostasi corrector amplifi
orkambi enhanc cftr activ support belief agent show
addit triplerx symdeko add-on pleas see exhibit
uss chamber correl improv sweat chlorid reduct
page
discoveri cftr
modul
novel cftr pipelin first-in-class amplifi
proteostasi develop three oral daili cftr modul cftr
potenti work open dysfunct cftr cell surfac permit ion
flow cftr corrector permit fold cftr protein reach cell
surfac membran potenti first-in-class amplifi
increas amount unfold cftr protein upon act
receiv fda breakthrough track orphan drug design
lack clinic benefit offer heterozyg cf patient minim function
mutat corrector potenti doublet led field develop triplerx
regimen vertex approach treat patient base addit
second next-gen corrector form triplerx increas amount fold cftr
transport cell surfac offer substrat upon kalydeco act
contrast proteostasi hypothes clinic benefit heterozyg
patient could improv increas amount unfold cftr cell offer
substrat corrector think increas concentr
unfold substrat could lead increas level fold substrat ultim
cftr potenti epitheli cell surfac importantli amplifi agnost
cftr mutat address popul cf patient vertex
identifi new class cftr modul proteostasi conduct high-throughput
screen small molecul identifi compound synergi potenti
corrector distinct mechan giuliano et al sla discoveri
characterist act new way compar classic potenti corrector
pti-ch potenti cftr activ uss chamber assay contrast
activ observ ivacaftor thu rule potenti properti
immunoblot analysi evalu pti-ch function corrector assess degre
cftr matur intriguingli pti-ch increas immatur matur
cftr lumacaftor increas slower-migr matur cftr
expect corrector mechan result corrobor hypothesi pti-
ch distinct mechan pure potenti correct
precis distinguish properti pti-ch lumacaftor assay use
cell design evalu select magnitud cftr
protein express specif surfac total express cftr protein
compar cell express transport protein act
control specif pti-ch increas total level nearli
vehicle-tr cell select total level increas
lumacaftor increas surfac cftr protein compar level interestingli
show declin total protein find relat pti-ch abil increas
cftr mrna evidenc increas measur rt-pcr hbe cell
importantli increas mrna observ homozygot
heterozygot suggest amplif agnost cftr mutat note
pti-ch result upregul cellular stress respons pathway could
trigger cell recogn increas mutant cftr protein guiliano et al sla
page
orkambi data
orkambi data
ad orkambi homozyg cf patient twenti cf patient
receiv qd four receiv placebo day top background
orkambi drug-drug interact patient one one
placebo mild thrombocytopenia discontinu combin orkambi
achiev mean absolut improv baselin compar
placebo mean rel improv day
importantli elisa analysi show averag maximum increas cftr protein
express nasal mucosa treat patient baselin find
support propos mechan publish guiliano et al increas
unfold fold cftr protein increas mrna level find particularli
import heterozyg individu receiv lung benefit
treatment orkambi phase ii studi boyl et al lancet
proteostasi perform subsequ vitro studi
bronchial epitheli cell line harbor rare heterozyg mutat show
amplifi combin orkambi augment respons increas level
immatur cftr protein effect replic patient-deriv nasal cultur
molinski et al embo mol clinic observ elev
cftr protein homozyg patient enhanc convict activ could
translat studi heterozyg patient would import inform
relev novel add-on strategi patient benefit orkambi
subgroup analysi show patient exhibit statist signific
improv lung function irrespect baselin may prove
differenti orkambi show statist signific benefit
patient baselin milder clinic manifest diseas
readout decemb proteostasi also confirm safeti triplerx
qd administ healthi volunt day safeti
unremark report lead treatment discontinu
pk data demonstr drug-drug interact data support advanc
doubl regimen well triplerx
octob proteostasi report complet phase ii data top orkambi
homozyg cf patient studi random patient three
escal dose level qd patient placebo
top background orkambi day safeti clean pulmonari
exacerb commonli report regardless treatment
group one discontinu group report prior dose
drug-drug interact improv sweat chlorid
cohort
also improv across dose cohort chang statist signific
pleas see exhibit dose compani select
clinic develop current assess parallel phase
combin studi symdkeo
page
dose depend sweat chlorid improv orkambi
studi
proteostasi report data two phase symdeko add-on studi
homozyg patient importantli data
inform potenti proteostasi strategi use proprietari amplifi corrector
add-on therapi patient alreadi receiv vertex therapi
phase studi evalu two undisclos daili dose amplifi
top symdeko versu symdeko alon homozyg cf
patient patient receiv background symdeko one month follow
addit placebo treatment day pleas see exhibit
see higher chanc success add strategi base robust activ
observ phase studi plu orkambi cf patient mean
absolut improv baselin compar placebo
day improv lung function also associ increas cftr
protein level nasal mucosa treat patient evidenc act
intend increas unfold fold protein
phase design symdeko homozyg patient
page
data
phase studi evalu qd dose background symdeko
compar symdeko alon homozyg cf patient patient
receiv symdeko month prior enter studi subsequ receiv
placebo day pleas see exhibit see higher bar
studi produc posit data base modest non-signific improv
observ phase studi top orkambi
symdeko potent orkambi like set higher efficaci control
phase design symdeko homozyg patient
earlier month north american cystic fibrosi confer nacfc
proteostasi report preliminari phase data first three four cohort pti-
homozyg cf patient data cutoff subject
random doublet across three dose cohort
placebo patient receiv treatment
day follow day follow-up baselin skew across cohort
sicker patient treatment group versu less sever placebo
baselin sweat chlorid consist across treatment placebo cohort
safeti clean combin pulmonari exacerb report
treatment follow-up period note pulmonari exacerb
frequent cite ae prior phase ii studi top background
orkambi lack pulmonari exacerb report studi may earli
make improv safeti profil pti doublet compar orkambi
dose-depend activ observ sweat chlorid across cohort
highest cohort improv
baselin day day though slight
declin activ observ day concern attribut
result small sampl size lack power larger studi correct
variabl furthermor statist signific declin sweat chlorid baselin
also report highest cohort improv mmol/l
mmol/l day respect pleas see exhibit
highest cohort dose patient report
data expect see continu dose depend activ could see
improv sweat chlorid cohort result
page
improv sweat chlorid statist signific
mean absolut chang baselin day
compar vertex symdeko phase symdeko data homozyg
patient show mean absolut chang baselin week
absolut chang sweat chlorid baselin mmol/l
note chang sweat chlorid larg observ day day
await long-term data inform durabl
proteostasi improv believ data offer earli evid
equival improv activ vertex symdeko day
triplerx hold tremend promis potenti treat upward patient
vertex lead competit could first cf tripl therapi market
late vertex report phase ii data two triplerx regimen
homozyg patient show averag improv baselin
two differ regiment day sweat chlorid improv
mmol/l mmol/l respect view data benchmark
phase data proteostasi triplerx regimen
proteostasi conduct phase studi proprietari triplerx regimen
homozyg cf patient patient
random one three cohort two treatment cohort receiv
singl agent day follow one two dose level triplerx day
third cohort patient receiv placebo total treatment period day pleas
see exhibit expect preliminari data lower dose cohort quarter
follow complet result
phase design triplerx homozyg patient
page
follow complet phase data proteostasi could begin global pivot
phase program triplerx cf
patient conting posit data expect proteostasi follow
regulatori preced set vertex triplerx regimen mean expect
registr trial fda primari efficaci endpoint absolut chang
baselin week safeti present anticip proteostasi
commenc pivot phase trial proprietari triplerx earli
base timelin anticip triplerx could gain fda approv
europ anticip net annual price similar vertex symdeko
project sale million million grow million
project european sale million million grow
billion total equat global cf sale million
million grow billion pleas see exhibit
cf foundat piper jaffray estim
page
unit fibrosi patient address cftr rx treat triplerx sale fibrosi patient address cftr rx treat triplerx sale triplerx cf sale
earli competitor cf
high barrier entri cf space biotech compani
strength clinic result cftr modul larger commerci player
current monopol global market earli stage compani like
proteostasi demonstr compel preclin clinic data proprietari
compound could see reach market next sever year view
flate discoveri lab competit proteostasi proprietari oral
potenti corrector
cover previous advanc novel
mrna deliv directli lung nebul form agnost
cftr mutat mean patient elig preclin data recent present
nacf build compel profil increas nasal potenti
differ observ cftr knockout rat model singl dose show potent
dose-depend upregul codon-optim mrna cftr increas
rat non-human primat compar endogen cftr
mrna product long-term experiment five weekli
nebul rat non-human primat detect hcftr protein hour
follow final dose recoveri period report
toler issu advers effect dose test
begun placebo-control phase i/ii singl multipl ascend
dose studi cf patient class ii mutat safeti toler
primari endpoint well assess deliveri bronchial epitheli cell
follow multipl dose efficaci measur includ post-treat chang
cftr protein chlorid channel activ expect data next year given
potenti treat cf patient view program potenti
competit cf space howev nebul mrna agent histor
show mix clinic result believ risk clinic studi
note data posit placebo-control design may enabl translat pursu
acceler path approv
proqr prqr cover develop eluforsen inhal
oligonucleotid therapi bind correct defect cftr mrna order treat
homozyg cf patient drug administ use atom devic
per week eluforsen demonstr posit clinic data two studi
proqr report phase poc data eluforsen homozyg heterozyg
patient primari endpoint nasal potenti differ npd
measur electr conduct nasal caviti correl cftr function
epitheli cell lower airway treatment show statist signific mean
chang chlorid transport day day homozyg
patient improv sodium transport time period
reach statist signific benefit observ heterozyg
second phase ib multipl ascend dose studi show mean absolut chang
sever patient correl cfq-r scale improv
mg dose proqr commun next step reveal plan
discov rna therapi treat class cf mutat could result
depriorit eluforsen advanc homozyg patient
view eluforsen present direct competit pressur proteostasi time
page
flate discoveri lab privat found non-profit lab develop novel
clinic candid treat cf compani two oral once-daili cftr modul
clinic corrector potenti next-gen version
molecul undergo preclin lead optim discoveri second
gener molecul also underway vitro data demonstr enhanc
activ plu compar symdeko hbe cell phase ii studi
europ on-going evalu safeti preliminari efficaci
homozyg patient phase studi assess drug-drug
interact plu healthi subject though phase ii-stag
compani flate yet present phase cf patient data view proteostasi
year ahead clinic
galapago glpg cover struggl remain competit cf field
follow underwhelm clinic readout proprietari cftr modul on-
off-again partner raymond decid last week acquir
world-wide right galapago cf pipelin million up-front million
potenti mileston base clinic data present believ galapago
cftr modul pose competit threat proteostasi june galapago
report data next-gen corrector ad background
orkambi homozyg patient show improv
versu placebo statist signific studi show
add-on agent improv lung function degre vertex
next-gen corrector shown triplerx last week galapago report top-lin
interim phase falcon data proprietari tripl combin potenti
corrector without homozyg
patient result even wors first studi show
result mean increas
triplerx offer addit benefit safeti follow-up assess
full data report thereaft inform continu clinic evalu believ
interim phase falcon data warrant clinic studi galapago triplerx
therefor view program competit proteostasi
novemb proteostasi form agreement astella develop
candid relat unfold protein respons upr pathway astella
purchas convert promissori note total million april agreement
extend decemb proteostasi intend name discoveri
candid year
term agreement proteostasi elig receiv research fund
support well develop mileston payment million
tier royalti payment rang mid-single-digit low double-digit percentag
page
presid ceo
ms meenu chhabra serv presid ceo proteostasi sinc
previous ceo allozyn sinc prior serv vice-president busi
develop licens novarti pharmaceut prior meenu chief
busi offic bioxel spa spin-off hoffmann-laroch ltd milan
research institut itali ms chhabra obtain york univers
 sc univers toronto
dr po-shun evp chief medic offic proteostasi sinc
previous serv svp clinic develop prior translat
medicin expert novarti institut biomed research dr
associ medic director vertex support clinic develop
registr kalydeco led cftr corrector program posit proof-of-
concept receiv biolog john hopkin univers
univers pennsylvania
dr marija zecev serv chief oper offic proteostasi sinc februari
serv previous chief busi offic sinc vice-president busi
develop sinc prior founder manag director zebra
ventur srl marija bring european perspect serv founder
coordin industri liaison offic italian cystic fibrosi foundat dr
zecev receiv molecular biolog univers belgrad ph
biochemistri institut physiolog univers zurich master
intern healthcar manag bocconi school manag milan
ms sheila wilson serv svp clinic develop oper prior ms wilson
serv vice-president global oper vice-president global clinic
oper prior serv vice-president
us medic oper inc
dr munoz chief scientif offic sinc march previous
evp drug discoveri prior serv director medicin chemistri molecular
librari probe product center network broad institut previous held
leadership posit merck recent director research laboratori
boston dr munoz receiv ph organ chemistri univers toronto
sc chemistri brock univers complet postdoctor train
scripp research institut
page
proteostasi gener revenu astella partnership revenu
million forecast revenu million
million
proteostasi invest million million
project invest increas million million
compani advanc cftr modul pivot cf studi
sg expens million million budget
compani spend million sg grow million
compani report net loss million per share
million project net loss million
million
proteostasi end cash million compani subsequ issu
million pti share rais gross proce million estim
proteostasi hold pro forma cash million
risk associ proteostasi common drug discovery/develop
compani includ clinic regulatori commerci cystic fibrosi competit
field larger better fund compani proteostasi drug could fail clinic
gain regulatori approv compani may unabl file new ind sign new
partnership proteostasi like requir addit capit could face futur
rate price target risk
rate oct close overweight price target base
non-gaap dilut ep disc thru risk includ cf drug may fail
clinic gain approv may meet sale expect vertex face
competit new cftr modul new modal
page
thousand except per share
research develop
gener administr
compani report piper jaffray estim
current disclosur inform compani found http //www piperjaffray com/researchdisclosur
